Attached files

file filename
8-K - STEPAN COrrd386558.htm
Exhibit 99.1         
 
 
FOR IMMEDIATE RELEASE:    CONTACT:    JAMES E. HURLBUTT 
         (847) 446-7500 

STEPAN REPORTS SECOND QUARTER RESULTS

     NORTHFIELD, Illinois, July 24, 2013 -- Stepan Company (NYSE: SCL) today reported higher second quarter net income of $22.7 million up 6 percent from $21.4 million in the year ago quarter. Diluted earnings per share was $0.99 versus $0.94 a year ago.

·      Sales volume grew by 4 percent for the quarter and 3 percent for the first six months.
 
·      Gross profit increased to $73.7 million compared to $73.4 million in the year ago quarter. Core operating margins remain stable when excluding higher priced methyl ester inventories built to support the Singapore start- up combined with contractual selling price lags.
 
  • Net income, excluding deferred compensation plan income, declined 10 percent to $20.4 million versus $22.6 million a year ago. Diluted EPS, excluding deferred compensation, was $0.89 versus $0.99 in the year ago quarter. Deferred compensation plan income was largely attributable to a decrease in the share price of the Company’s common stock, which declined by $7.49 per share during the quarter. Surfactant segment earnings declined on an unfavorable sales mix and utilization of higher cost raw materials. Polymer and Specialty Product segments both posted higher earnings.
     
     
  • Operating expenses, excluding deferred compensation, increased by $4.3 million or 12 percent during the quarter. Approximately $1.1 million of the increase relates to growth initiatives including patent expenditures for metathesis technologies, acquisition costs related to the business acquired from Bayer Material Science and European product registration costs for our Singapore produced methyl esters. The majority of the remaining higher spending relates to salaries, travel and legal expenses to support global growth opportunities outside of North America, including support of our Lipid Nutrition business in Europe.
     
     
  • Year-to-date income declined 4 percent to $41.8 million compared to $43.7 million a year ago.
     

    • Year-to-date net income, excluding deferred compensation plan expense, was $41.9 million, down 9 percent from $46.2 million a year ago.
    SUMMARY                         
     
        Three Months Ended June 30    Six Months Ended June 30 


    ($ in thousands, except                 %            % 
    per share amounts)         2013    2012    Change         2013    2012    Change 
     
    Net Sales    $474,445    $470,231    + 1    $930,991    $935,500           - 
     
    Net Income    22,742    21,425    + 6    41,776    43,727    - 4 
     
    Net Income Excluding                         
       Deferred Compensation*    20,361    22,555    -10    41,876    46,195    -9 
     
    Earnings per Diluted Share    $0.99    $0.94    + 5    $1.82    $1.93    - 6 
     
    Earnings per Diluted Share                         
       Excluding Deferred                         
       Compensation    $0.89    $0.99    -10    $1.82    $2.04    - 11 
     
    * See Table II for a discussion of deferred compensation plan accounting.         
     
     
    SEGMENT RESULTS                         
     
        Three Months Ended June 30    Six Months Ended June 30 


    ($ in thousands)                 %            % 
             2013    2012    Change         2013    2012    Change 
     
    Net Sales                         
         Surfactants    $331,087    $335,114    - 1    $671,060    $682,270    - 2 
         Polymers    121,325    113,923    + 6    217,323    210,672    +3 
         Specialty Products    22,033    21,194    + 4    42,608    42,558    0 



    Total Net Sales    $474,445    $470,231    + 1    $930,991    $935,500    0 

     
     
     Percentage Change in Net Sales                     
     
        Three Months Ended    Six Months Ended     
            June 30        June 30     
     Volume        + 4%            + 3%     
     Selling Price        - 3%            - 3%     
     Foreign Translation        0%            0%     

           Total        + 1%            0%     

    The decline in selling prices was attributable to lower commodity raw material costs.

    2


    • Surfactant sales volume rose by 5 percent with all regions contributing. Sales of consumer cleaning products led the growth. Surfactants used in agricultural products continued to deliver strong volume growth. Sales of functional surfactants used in oilfield applications, including enhanced oil recovery declined. Latin American sales volume grew by 15 percent with Brazil contributing the majority of the increase.
    • Polymer sales volume grew by 1 percent. Polyol, used primarily in insulation foam, grew by 6 percent with both North American and Europe contributing to the increase. Lower phthalic anhydride sales volume partially offset the growth in polyol volume.
    • Specialty Products net sales rose 4 percent on a favorable sales mix.

    Gross profit grew by less than 1 percent to $73.7 million.

    • Surfactant gross profit declined by 7 percent to $48.3 million. Lower North
      American sales of functional surfactants into the oilfield market including enhanced oil recovery combined with reduced profitability from biodiesel sales contributed to the weaker results. North American consumer products earnings were reduced by consumption of higher cost raw material inventories. Europe and Latin American surfactant profits were both higher on improved consumer product sales volume.
    • Polymer gross profit grew by 15 percent to $19.9 million due to the 6 percent growth in polyol volume in North America and Europe.
      Contribution from China declined $1.1 million as the plant shut down, as planned, to relocate at the government’s request. Customers will continue to be supplied from Stepan’s US and European plants and toll production in China, which will result in lower margins. Construction of our new plant in China is anticipated to take 18 to 24 months. The polyol business acquired from Bayer Material Science added a small contribution to the quarter.
    • Specialty Products gross profit grew by 19 percent to $6.6 million. A favorable sales mix of our nutritional supplement and pharmaceutical products led to the improvement.

    3


    OPERATING EXPENSES                         
     
        Three Months Ended June 30    Six Months Ended June 30 



    ($ in thousands)            %                 % 
           2013    2012    Change    2013    2012    Change 
     
    Selling    $14,440    $12,985    + 11    $28,168    $26,636    + 6 
    Administrative – General    15,151    12,629    + 20    29,569    26,081    + 13 
    Administrative – Deferred                         
     Compensation*    (3,621)    1,457    NM    1,312    4,957    - 74 
    Research, development                         
    and technical service    11,868    11,504    + 3    23,195    22,285    + 4 


         Total    $37,838    $38,575    - 2    $82,244    $79,959    + 3 

    *      See Table II for a discussion of deferred compensation plan accounting.
     
      ·      Selling expense rose 11 percent due to higher bad debt provisions, travel expense and consulting. The increased bad debt provision primarily relates to European customer risk.
     
      ·      Administrative general expense rose 20 percent primarily due to $1.1 million of higher legal and patent expenses for growth initiatives in metathesis technologies and nonrecurring costs associated with the Company’s acquisition of the North American polyester resins business from Bayer Material Science during the second quarter. The majority of the remaining higher spending relates to salaries, travel and legal expenses to support global growth opportunities outside of North America, including support of our Lipid Nutrition business in Europe.
     

    INCOME TAXES

    The year-to-date effective tax rate was 27.5 percent compared to 31.7 percent a year ago. The lower rate was due to the retroactive reenactment of the U.S. Research and Development tax credit which resulted in the 2012 and 2013 credit all being recognized in the 2013 income tax provision.

    BALANCE SHEET                         
     
             ($ in millions)    6/30/13    3/31/13    12/31/12 
             Net Debt                         
                   Total Debt    $    285.4    $    193.9    $    182.4 
                   Cash        106.9        54.8        76.9 




                         Net Debt    $    178.5    $    139.1    $    105.5 
             Equity        508.7        494.9        480.9 






             Net Debt + Equity    $    687.2    $    634.0    $    586.4 
     
                         Net Debt / (Net Debt + Equity)        26.0%    21.9%    18.0% 

    On June 27, 2013, the Company secured a new $100 million private placement and repaid $60 million of U.S. revolver borrowings that had been used to fund the Bayer

    4


    acquisition on June 3, 2013. The new 3.86% notes have a final maturity of 12 years with straight-line amortization in years 6 through 12, resulting in an average life of 9 years. Terms and conditions are substantially equivalent to those in our existing long-term debt agreements.

    Capital expenditures were $ 21.0 million during the quarter and $ 42.0 for the first half of 2013.

    DIVIDEND

    The Board of Directors of Stepan Company declared a quarterly cash dividend on its common stock of $0.16 per share on July 23, 2013. The dividend is payable on September 13, 2013, to common stockholders of record on August 30, 2013.

    OUTLOOK

    “Despite the lower first half operating results, we remain optimistic about our long-term growth,” said F. Quinn Stepan, Jr., President and Chief Executive Officer.

    Global surfactant consumer product volumes should continue to grow, particularly in Brazil. Higher raw material cost inventory built to support our Singapore plant start-up and the subsequent decline in commodity prices, negatively impacted our first half surfactant margins by $3.0 million and potentially up to $1.7 million in the second half. The Singapore methyl ester plant is operational and should contribute to earnings in the second half. Surfactants sold for use in enhanced oil recovery are expected to improve compared to the slow first half. Demand for agricultural surfactants should remain strong.

    The polymer segment is experiencing steady improvement in polyol volume after a slow start due to protracted winter weather delaying many roof insulation projects. The second quarter acquisition of the North America polyester resin business from Bayer Material Science should be modestly accretive to earnings in 2013 and more so after we add capacity to manufacture additional polyol products for the coating, adhesive, sealant and elastomers (CASE) markets.

    “The slow start to the year will make full year earnings growth an aggressive target. We will continue to pursue investments that can accelerate our growth,” said Mr. Stepan.

    CONFERENCE CALL

    Stepan Company will host a conference call to discuss the second quarter results at 2:00 p.m. Eastern Daylight Time on July 24, 2013. To listen to a live webcast of this call, please go to our Internet website at: www.stepan.com, click on investor relations, next click on conference calls and follow the directions on the screen.

    Stepan Company, headquartered in Northfield, Illinois, is a leading producer of specialty and intermediate chemicals used in household, industrial, personal care, agricultural,

    5


    food and insulation related products. The common and the convertible preferred stocks are traded on the New York Stock Exchange under the symbols SCL and SCLPR.

    * * * * *
    Tables follow

    Except for historical information, all other information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Stepan Company’s Form 10-K, Form 8-K and Form 10-Q reports and exhibits to those reports, and include (but are not limited to), prospects for our foreign operations, foreign currency fluctuations, certain global and regional economic conditions, the probability of future acquisitions and the uncertainties related to the integration of acquired businesses, the probability of new products, the loss of one or more key customer or supplier relationships, the costs and other effects of governmental regulation and legal and administrative proceedings, including the expenditures necessary to address and resolve environmental claims and proceedings, and general economic conditions. These forward-looking statements are made only as of the date hereof, and Stepan Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

    6


                            Table I 
     
    STEPAN COMPANY
    Statements of Income
    For the Three and Six Months Ended June 30, 2013 and 2012
    (Unaudited – 000’s Omitted)
     
     
        Three Months Ended        Six Months Ended     
            June 30                June 30         








                    %                % 
             2013         2012    Change     2013         2012    Change 
     
     
     
    Net Sales    $474,445    $470,231     +    1    930,991    $935,500     -    - 
    Cost of Sales    400,738    396,835     +    1    784,584    785,320     -    - 
       Gross Profit    73,707    73,396     +    -    146,407    150,180     -    3 
     
    Operating Expenses:                                 
       Selling    14,440    12,985     +    11    28,168    26,636     +    6 
       Administrative    11,530    14,086     -    18    30,881    31,038     -    1 
       Research, development                                 
    and technical services    11,868    11,504     +    3    23,195    22,285     +    4 
        37,838    38,575     -    2    82,244    79,959     +    3 
     
    Operating Income    35,869    34,821     +    3    64,163    70,221     -    9 
    Other Income (Expense):                                 
       Interest, net    (2,329)    (2,086)     +    12    (4,508)    (4,690)     -    4 
       Loss from equity in joint ventures    (1,323)    (1,300)     +    2    (2,736)    (2,441)     +    12 
       Other, net    (17)    83        NM    554    1,148     -    52 

        (3,669)    (3,303)     +    11    (6,690)    (5,983)     +    12 
     
    Income before Income Taxes    32,200    31,518     +    2    57,473    64,238     -    11 
    Provision for Income Taxes    9,546    10,007     -    5    15,822    20,363     -    22 
    Net Income    22,654    21,511     +    5    41,651    43,875     -    5 
     
    Net (Income) Loss Attributable                                 
    to the Noncontrolling Interests    88    (86)        NM    125    (148)        NM 


     
    Net Income Attributable to                                 
       Stepan Company    $22,742    $21,425     +    6    $41,776    $43,727     -    4 

    Net Income Per Common Share                                 
    Attributable to Stepan Company                                 
       Basic    $1.01    $1.01        -    $1.85    $2.06    -    10 
       Diluted    $0.99    $0.94    +    5    $1.82    $1.93    -    6 
     
    Shares Used to Compute Net                                 
    Income Per Common Share                                 
    Attributable to Stepan Company                                 
       Basic    22,559    21,100    +    7    22,512    21,074    +    7 
       Diluted    22,917    22,714    +    1    22,903    22,690    +    1 

    7


    Table II

    Deferred Compensation Plan

    The full effect of the deferred compensation plan on quarterly pretax income was $3.8 million of income versus expense of $1.8 million last year. The accounting for the deferred compensation plan results in income when the price of Stepan Company common stock or mutual funds held in the plan fall and expense when they rise. The Company also recognizes the change in value of mutual funds as investment income or loss. The quarter end market prices of Stepan Company common stock are as follows:

                 2013         2012        2011 





    6/30    3/31    12/31     6/30    3/31    12/31 
     
    $55.61    $63.10    $55.54    $47.09    $43.90    $40.08 

    The deferred compensation expense income statement impact is summarized below:

        Three Months Ended June 30    Six Months Ended June 30 


    ($ in thousands)    2013    2012    2013    2012 
     
    Deferred Compensation                 
       Administrative (Expense) Income    $3,621    $(1,457)    $(1,312)    $(4,957) 
       Other, net – Mutual Fund Gain (Loss)    220    (365)    1,150    977 
             Total Pretax    3,841    $(1,822)    (162)    $(3,980) 
     
    Total After Tax    $2,381    $(1,130)    $100    $(2,468) 
     
    Reconciliation of non-GAAP net income:             
     
        Three Months Ended June 30    Six Months Ended June 30 


    ($ in thousands)    2013    2012    2013    2012 
     
    Net income excluding deferred                 
       compensation    $20,361    $22,555    $41,876    $46,195 
    Deferred compensation plan (expense)                 
       income    2,381    (1,130)    (100)    (2,468) 
    Net income as reported    $22,742    $21,425    $41,776    $43,727 
     
    Reconciliation of non-GAAP EPS:             
     
        Three Months Ended June 30    Six Months Ended June 30 


        2013    2012    2013    2012 
     
    Earnings per diluted share excluding                 
       deferred compensation    $0.89    $0.99    $1.82    $2.04 
    Deferred compensation plan (expense)                 
       income    0.10    (0.05)    --    ( 0.11) 

    Earnings per diluted share    $0.99    $0.94    $1.82    $1.93 

    The Company believes that certain non-GAAP measures, when presented in conjunction with comparable GAAP (Generally Accepted Accounting Principles) measures, are useful because that information is an appropriate measure for evaluating the Company’s operating performance. Internally, the Company uses this non-GAAP information as an indicator of business performance, and evaluates management’s effectiveness with specific reference to these indicators. These measures should be considered in addition to, neither a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

    8


    Table III

    Effects of Foreign Currency Translation

    The Company’s foreign subsidiaries transact business and report financial results in their respective local currencies. As a result, foreign subsidiary income statements are translated into U.S. dollars at average foreign exchange rates appropriate for the reporting period. Because foreign exchange rates fluctuate against the U.S. dollar over time, foreign currency translation affects period-to-period comparisons of financial statement items (i.e. because foreign exchange rates fluctuate, similar period-to-period local currency results for a foreign subsidiary may translate into different U.S. dollar results). Below are tables that present the effect that foreign currency translation had on the changes in consolidated net sales and various income line items for the quarter and six months ended June 30, 2013.

        Three Months         
        Ended June 30         

                    Increase Due to 
        2013    2012    Increase    Foreign Translation 
     
    Net Sales    $474.4    $470.2             $4.2    $1.5 
    Gross Profit    73.7    73.4    0.3                             0.1 
    Operating Income    35.9    34.8    1.1                             0.1 
    Pretax Income    32.2    31.5    0.7                             0.1 
     
     
        Six Months         
        Ended June 30         

                    Increase/(Decrease) 
                    Due to 
        2013    2012    (Decrease)    Foreign Translation 
     
    Net Sales    $931.0    $935.5    $(4.5)    $1.2 
    Gross Profit    146.4    150.2    (3.8)    (0.1) 
    Operating Income    64.2    70.2    (6.0)    - 
    Pretax Income    57.5    64.2    (6.7)    - 

    9


            Table IV 
     
    Stepan Company
    Consolidated Balance Sheets
    June 30, 2013 and December 31, 2012
     
                 2013               2012 
        June 30    December 31 
    ASSETS         
    Current Assets    $595,969    $523,078 
    Property, Plant & Equipment, Net    464,446    422,022 
    Other Assets    63,312    40,378 
    Total Assets    $1,123,727    $985,478 
    LIABILITIES AND EQUITY         
    Current Liabilities    $260,803    $247,167 
    Deferred Income Taxes    9,725    9,200 
    Long-term Debt    246,696    149,564 
    Other Non-current Liabilities    97,819    98,667 
    Total Stepan Company Stockholders’ Equity    506,885    478,985 
    Noncontrolling Interest    1,799    1,895 
       Total Liabilities and Equity    $1,123,727    $985,478 


    10